Burning Rock Biotech Limited reported unaudited financial results for Q4 and full year 2025, with full-year revenue increasing 4.6% to RMB539.6 million and net loss narrowing significantly to RMB55.3 million from RMB346.6 million in 2024. The company highlighted the granting of a core U.S. patent for its ELSA-seq technology and regulatory progress for its OncoScreen BCMatch Tissue Kit.
Key takeaways
Full year 2025 revenue was RMB539.6 million (US$77.2 million), a 4.6% increase from RMB515.8 million in 2024.
Net loss for 2025 narrowed to RMB55.3 million (US$7.9 million), compared to a net loss of RMB346.6 million in 2024.
Q4 2025 revenue remained relatively stable at RMB126.3 million (US$18.1 million) compared to RMB126.0 million in the same period of 2024.
Pharma research and development services revenue grew 34.5% year-over-year to RMB155.5 million (US$22.2 million) for the full year 2025.
Operating expenses decreased 36.4% year-over-year to RMB457.8 million (US$65.5 million) for the full year 2025.
The core patent for ELSA-seq technology (Patent No.: US 12460202 B2) was granted by the USPTO.